Trump Proposes Pharma Tariffs Raising U.S. Drug Costs, Supply Risks

President Donald Trump's proposal to impose tariffs on imported pharmaceuticals aims to encourage domestic drug manufacturing but is expected to raise costs for everyday prescription medications like insulin, painkillers, and chemotherapy drugs. Experts warn that tariffs on drugs, many of which are imported from countries like Ireland, Germany, and Switzerland, would increase prices for pharmacies and insurers, with these costs ultimately passed on to patients. The tariffs could also disrupt supply chains, potentially leading to shortages of generic drugs. Industry stakeholders across manufacturing, distribution, and retail sectors are concerned about the broad financial and logistical impacts of these tariffs. Additionally, a recent U.S.-UK trade agreement requires the NHS to consider higher prices for American drugs to avoid future tariffs, highlighting international repercussions linked to Trump's trade policies. Overall, while the tariffs are intended to promote U.S. drug production, they risk making essential medicines less affordable for Americans and complicating international pharmaceutical trade relations.